Profile picture of Adrian Selim

Dr Adrian Selim

Profile picture of Adrian Selim

MBBS, FRCPA, FRACP

Clinical Haematologist
Call
Email
Referrals

Dr Adrian Selim is an Arabic-speaking haematologist who speaks fluent English, Arabic, French and some Mandarin and Spanish. He prides himself on treating every patient with respect and empathy, and tailors their management to suit their individual needs. He is committed to providing patients and their loved ones with ample information and support to ensure they achieve the best possible outcome.

Biography

Dr Adrian Selim is a clinical and laboratory haematologist at Icon Cancer Centre Revesby, with extensive expertise in malignant haematology. In 2009 Dr Selim completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at Bond University and subsequently undertook haematology training in Sydney’s Eastern hospital network. He completed a bone marrow transplant fellowship at the Bristol Royal Infirmary, United Kingdom and in 2019 became the inaugural cell therapies fellow at Peter MacCallum Cancer Centre. During this fellowship he gained extensive experience in novel immunotherapies, particularly chimeric antigen receptor T-cell therapy (CAR-T), as well as a strong clinical research foundation.

Dr Selim is a strong advocate for cell therapy and clinical research, and has authored numerous peer-reviewed publications. He is a fellow of both the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists of Australasia (FRCPA). Outside of Icon, Dr Selim has worked as a haematologist at Cairns Hospital, Liverpool Hospital and St Vincent’s Hospital, Sydney. His clinical experience covers a wide range of malignant and non-malignant blood disorders including acute and chronic leukaemias, lymphoma, myeloma, myeloproliferative disorders and myelodysplastic syndromes.

Publications

  • Early Administration of Partially HLA Matched Third Party Virus-Specific T-Cells in Conjunction with Antiviral Treatment for Initial Viral Infection after Allogeneic Stem Cell Transplant Is Safe and Leads to High Rates of Viral Control. W. Jiang, G. Sutrave, S. Avdic, L.E. Clancy, S. Inam, E. Atkins, C.M. Bateman, A.G. Selim, V. Antonenas, J. Street, R. Simms, P.J. Shaw, D. Ritchie, E. Blyth & D.J. Gottlieb. Blood, 2021; 138 (Supplement 1): 255.

  • An atypical case of Epstein-Barr virus-positive plasma cell post-transplant lymphoproliferative disorder successfully treated with adoptive cell therapy. Elliott, S. Avdic, A.G. Selim, L. Clancy, E. Atkins, E. Blyth, D. Ritchie, D. Gottlieb & A. Bajel. British Journal of Haematology, 2021.

  • CAR-T cell therapy: practical guide to routine laboratory monitoring.G. Selim, A. Minson, P. Blombery, M. Dickinson, S.J. Harrison & M.A. Anderson. Pathology, 2021; 53: 408-415.

  • Chimeric antigen receptor T-cell therapy for haematological malignancies.G. Selim & C.S. Tam. Medical Journal of Australia 2020; 213(9): 404-406.e1.

  • Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial). Gottlieb, S. Avdic, W. Jiang, L. Clancy, P.J. Shaw, C.M. Baterman, E. Atkins, V. Antonenas, A.G. Selim, G. Sutrave, D. Collins, D. Ritchie, E. Blythe, J. Street & R. Simms. Blood, 2019; 134 (Supplement_1): 251.

Special Interests

Dr Adrian Selim accepts referrals for malignant and non-malignant blood disorders, with a special clinical interest in:

  • Leukaemia
  • Lymphoma
  • Multiple myeloma
  • Myelodysplasia
  • Myeloproliferative neoplasms

Languages Spoken

  • Arabic
  • English
  • Spanish

Icon Locations

Visiting Locations

  • Nepean Hospital

Affiliations & Memberships

  • European Haematology Association (EHA)
  • International Society of Cell and Gene Therapy (ISCT)
  • eviQ Cellular Therapies Reference Committee
  • Royal Australasian College of Physicians (RACP)
  • Royal College of Pathologist of Australasia (RCPA)

Publications

  • Early Administration of Partially HLA Matched Third Party Virus-Specific T-Cells in Conjunction with Antiviral Treatment for Initial Viral Infection after Allogeneic Stem Cell Transplant Is Safe and Leads to High Rates of Viral Control. W. Jiang, G. Sutrave, S. Avdic, L.E. Clancy, S. Inam, E. Atkins, C.M. Bateman, A.G. Selim, V. Antonenas, J. Street, R. Simms, P.J. Shaw, D. Ritchie, E. Blyth & D.J. Gottlieb. Blood, 2021; 138 (Supplement 1): 255.

  • An atypical case of Epstein-Barr virus-positive plasma cell post-transplant lymphoproliferative disorder successfully treated with adoptive cell therapy. Elliott, S. Avdic, A.G. Selim, L. Clancy, E. Atkins, E. Blyth, D. Ritchie, D. Gottlieb & A. Bajel. British Journal of Haematology, 2021.

  • CAR-T cell therapy: practical guide to routine laboratory monitoring.G. Selim, A. Minson, P. Blombery, M. Dickinson, S.J. Harrison & M.A. Anderson. Pathology, 2021; 53: 408-415.

  • Chimeric antigen receptor T-cell therapy for haematological malignancies.G. Selim & C.S. Tam. Medical Journal of Australia 2020; 213(9): 404-406.e1.

  • Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial). Gottlieb, S. Avdic, W. Jiang, L. Clancy, P.J. Shaw, C.M. Baterman, E. Atkins, V. Antonenas, A.G. Selim, G. Sutrave, D. Collins, D. Ritchie, E. Blythe, J. Street & R. Simms. Blood, 2019; 134 (Supplement_1): 251.

Search

Become a patient